Reviewing Guided Therapeutics (OTCMKTS:GTHP) and Hyperfine (NASDAQ:HYPR)

Hyperfine (NASDAQ:HYPR – Get Rating) and Guided Therapeutics (OTCMKTS:GTHP – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.

Valuation and Earnings

This table compares Hyperfine and Guided Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$5.83 million	17.20	-$64.85 million	($3.59)	-0.40
Guided Therapeutics	$80,000.00	179.23	-$2.07 million	N/A	N/A

Guided Therapeutics has lower revenue, but higher earnings than Hyperfine.

Risk & Volatility

Hyperfine has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500.

Profitability

This table compares Hyperfine and Guided Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperfine	-1,479.40%	-54.01%	-49.87%
Guided Therapeutics	-4,276.71%	N/A	-130.07%

Insider and Institutional Ownership

27.6% of Hyperfine shares are held by institutional investors. Comparatively, 9.8% of Guided Therapeutics shares are held by institutional investors. 26.1% of Hyperfine shares are held by company insiders. Comparatively, 66.8% of Guided Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Hyperfine and Guided Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	0	1	2	0	2.67
Guided Therapeutics	0	0	0	0	N/A

Hyperfine currently has a consensus price target of $4.30, indicating a potential upside of 202.82%. Given Hyperfine’s higher possible upside, equities research analysts clearly believe Hyperfine is more favorable than Guided Therapeutics.

Summary

Hyperfine beats Guided Therapeutics on 6 of the 11 factors compared between the two stocks.

About Hyperfine

(Get Rating)

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products. The company's products include Swoop Portable MR imaging system, which offers neuroimaging at the point of care, as well as informs the timely diagnosis and treatment of acute conditions in a wide range of clinical settings. Hyperfine, Inc. was incorporated in 2014 and is based in Guilford, Connecticut.

About Guided Therapeutics

(Get Rating)

Guided Therapeutics, Inc. is a medical technology company, which engages in developing medical devices. It also focuses on the selling and marketing of its LuViva advanced cervical scan non-invasive cervical cancer detection device. The company was founded by Shabbir Bakir Bambot and Mark L. Faupel on October 27, 1992 and is headquartered in Norcross, GA.